IP Library Granted Patent US 8,092,793
Granted Patent B2
US 8,092,793 · App. 11/763,094 · Granted Jan 10, 2012

Treating inflammatory bowel disease with live bacteria

Assignee: Qingdao East Sea Pharmaceuticals, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,092,793
App. No.
11/763,094
Granted
Jan 10, 2012
Kind
B2
Abstract

This invention relates to using live beneficial bacteria for treating inflammatory bowel disease, such as ulcerative colitis and Crohn's disease.

Claims (16)

1. A method of treating an inflammatory bowel disease, comprising:

identifying a subject in need thereof, and

administering to the subject a composition which contains an effective amount of Clostridium butyricum CGMCC No. 0313.1.

2. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease.

3. The method of claim 2 , wherein the composition contains an effective amount of Clostridium butyricum CGMCC No. 0313.1.

4. The method of claim 3 , wherein the composition contains 1 ×10 6 colony forming unit/g to 1 ×10 12 colony forming unit/g Clostridium butyricum CGMCC No. 0313.1.

5. The method of claim 1 , wherein the composition contains an effective amount of Clostridium butyricum CGMCC No. 0313.1.

6. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.

7. The method of claim 6 , wherein the composition contains an effective amount of Clostridium butyricum CGMCC No. 0313.1.

8. The method of claim 7 , wherein the composition contains 1 ×10 6 colony forming unit/g to 1 ×10 12 colony forming unit/g Clostridium butyricum CGMCC No. 0313.1.

9. The method of claim 1 , wherein the effective amount of Clostridium butyricurn CGMCC No. 0313.1 is within the range of 1 ×10 6 to 1 ×10 12 colony forming unit per day.

10. The method of claim 1 , wherein the composition is administered orally.

11. The method of claim 1 , wherein the composition is a pharmaceutical composition.

12. The method of claim 11 , wherein the pharmaceutical composition is formulated in a form of tablet, capsule, powder, or liquid.

13. The method of claim 11 , wherein the pharmaceutical composition contains 1 ×10 6 colony forming unit/g to 1 ×10 12 colony forming unit/g live beneficial bacteria.

14. The method of claim 1 , wherein the composition is a food product or a food supplement.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2007
From: CUI, YUNLONG
To: QINGDAO EAST PHARMACEUTICAL, LTD.
Reel/Frame 019816/0942 →
Priority Claims (2)
CN 2004 1 0098660 · Dec 15, 2004 · national
CN 2007 1 0002692 · Jan 29, 2007 · national
Continuity (2)
Continuation In Part 11191712 · Jul 28, 2005
Related Publication 20080003207A1 · Jan 3, 2008